ClinicalTrials.gg
CompletedNCT01438814Updated Nov 25, 2014Results posted

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

A Phase 4 interventional study of metformin placebo and linagliptin placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 90 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-11-25.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
689
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
10th of 67
689 · median 175
Started
2011
with 1 other
Phase 4
22 of 67
1 open now
Registered
26th of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 2 that started in 2011, is one of 22 in phase 4, and was the 26th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The aim of this study is to investigate the impact of the combination therapy of linagliptin and metformin at submaximal doses in reduction of Glycosylated haemoglobin (HbA1c) and metformin pre-specified gastro-intestinal (GI) side effects in treatment naive patients of with type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Type 2 diabetes mellitus (T2DM) prior to ;
  2. Male and female patients on diet and exercise regimen who are drug naive, defined as absence of any oral antidiabetic therapy or insulin for 12 weeks prior to randomization
  3. Glycosylated (HbA1c) >/= 7.0% (53 mmol/mol) to \</= 10.0% (86 mmol/mol) at visit 1 (screening);
  4. Age>/=18 and \</=80 years at visit 1(screening);
  5. (BMI)\</= 45kg/m2 at visit 1 (screening);
  6. Signed and dated written informed consent by date of visit 1 in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion criteria:

  1. Uncontrolled hyperglycaemia with a glucose level >240 mg/dl (13.3mmol/L) after an overnight fast during screening/placebo run-in and confirmed by a second measurement (Not on the same day);
  2. Treatment with any oral antidiabetic drug or insulin within 12 weeks prior to randomization
  3. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris),stroke or Transient ischemia attack () within 3 months prior to ;
  4. Indication of liver disease/Impaired hepatic function, defined by serum levels of either (ALT or SGPT), alanine aminotransferase (AST or SGOT), or alkaline phosphatase above 3 x (ULN) as determined at visit 1 and/or run-in phase,
  5. Impaired renal function, defined as \< 60ml/min (moderate or severe renal impairment, modification of diet in renal disease (MDRD) formula) as determined during screening or at run-in phase
  6. Bariatric surgery within the past two years and other gastrointestinal surgeries that induced chronic malabsorption
  7. Medical history of Cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years
  8. Blood dyscrasia or any other disorders causing haemolysis or unstable Red Blood Cell (eg. malaria, babesiosis, haemolytic anemia)
  9. Known history of pancreatitis and chronic pancreatitis
  10. to metformin according to the local label
  11. Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen etc) leading to unstable body weight
  12. Current treatment with systemic at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM
  13. Pre-menopausal women (last menstruation less than 1 year prior to informed consent) who:

    1. are nursing or pregnant or
    2. are of and are not practicing an acceptable method of , or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial or who do not agree to continue contraception for at least 30 days after the last dose of study drug. Acceptable methods of birth control include tubal ligation, transdermal patch, intra-uterine devices/systems(IUDs/IUSs), oral, implantable, or injectable contraceptives, complete sexual abstinence (if acceptable by local authorities), double barrier method and vasectomized partner.
  14. Alcohol or drug abuse within 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake
  15. Participation in another trial with application of any drug within 30 days prior to informed consent
  16. Any other clinical condition that would jeopardize patients safety while participating in this trial
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
689 participants (actual)

Study arms

  • Experimental
    linagliptin + metformin

    patients to receive linagliptin +metformin QD

    Drug: metformin · Drug: linagliptin

  • Active comparator
    metformin

    patients to receive metformin BID

    Drug: metformin placebo · Drug: linagliptin placebo · Drug: metformin

Interventions

  • Drugmetformin placebo

    metformin placebo tablets 500mg

  • Druglinagliptin placebo

    linagliptin placebo tablets 5mg

  • metformin tablets 500mg

  • metformin tablets 500 mg

  • linagliptin tablets 5mg

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment

    Adjusted mean change in HbA1c from baseline at Week 14 was analysed using an ANCOVA model. The Model included treatment and continuous baseline HbA1c.

    Time frame: Baseline and 14 weeks

Secondary outcomes

  1. Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 14 Weeks of Treatment, on no Occurrence of Moderate or Severe Gastrointestinal (GI) Side Effects During 14 Weeks of Treatment

    The proportion of patients who achieved all the targets in a composite endpoint (HbA1c below 7.0% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe gastrointestinal (GI) side effects of metformin, as assessed by the investigators during 14 weeks of treatment)

    Time frame: 14 weeks

  2. Occurence of Metformin Pre-specified Moderate to Severe GI Side Effects Assessed by Investigators During 14 Weeks of Treatment

    Proportion of patients who experienced at least one metformin pre-specified moderate or severe GI side effect during 14 weeks

    Time frame: 14 weeks

  3. Change From Baseline in Fasting Plasma Glucose (FPG) After 14 Weeks of Treatment

    Means are adjusted by treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.

    Time frame: Baseline and 14 weeks

  4. Metformin Pre-specified GI Symptom Intensity Score Assessed by Investigators During 14 Weeks of Treatment

    Patients could experience multiple events, therefore, multiple answers were possible for each patient.

    Time frame: 14 weeks

  5. Metformin Pre-specified GI Symptom Intensity Score Assessed by Patients During 14 Weeks of Treatment

    The intensity of the GI side effects was also assessed by the patients using VAS scaled from 0 to 10; higher scores indicate more severe events. Means are adjusted by treatment and continuous baseline HbA1c.

    Time frame: 14 weeks

  6. Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <6.5% After 14 Weeks of Treatment, and no Occurrence of Moderate or Severe Metformin Pre-specified GI Side Effects Assessed by Investigators

    The proportion of patients who achieved all the targets in a composite endpoint (HbA1c below 6.5% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).

    Time frame: 14 weeks

  7. Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment)

    The proportion of patients who achieved a relative efficacy response (HbA1c lowering by at least 0.5% after 14 weeks of treatment).

    Time frame: 14 weeks

  8. Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment)

    The proportion of patients who achieved a relative efficacy response (HbA1c lowering by at least 0.8% after 14 weeks of treatment).

    Time frame: 14 weeks

  9. Composite Endpoint of Occurence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment) and no Occurence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by the Investigators During 14 Weeks

    The proportion of patients who achieved all the targets in a composite endpoint (HbA1c lowered by at least 0.5% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).

    Time frame: 14 weeks

  10. Change From Baseline in Body Weight by Visit at Week 14

    Means are adjusted by treatment, continuous baseline HbA1c and continuous baseline weight

    Time frame: Baseline and 14 weeks

  11. Composite Endpoint of Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment) and no Occurrence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by Investigators During 14 Weeks

    The proportion of patients who achieved all the targets in a composite endpoint (HbA1c lowered by at least 0.8% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).

    Time frame: 14 weeks

  12. Change From Baseline in HbA1c Over Time

    Means are adjusted by treatment and continuous baseline HbA1c

    Time frame: Baseline, 2 weeks and 8 weeks

07

Results

Posted Jun 3, 2014

Participant flow

Participant flow — Overall Study
MilestoneLina 5mg + Met qdMet Bid
Started344345
Completed330331
Not completed1414
Withdrew: Adverse event33
Withdrew: Protocol violation12
Withdrew: Lost to follow-up43
Withdrew: Withdrawal by subject42
Withdrew: Other24

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment

Adjusted mean change in HbA1c from baseline at Week 14 was analysed using an ANCOVA model. The Model included treatment and continuous baseline HbA1c.

Time frame:
Baseline and 14 weeks
Reported as:
Mean · percent
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment
percentLina 5mg + Met qdMet Bid
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment-0.99 ± 0.05-0.98 ± 0.04
Statistical analysis
  • Lina 5mg + Met qd vs Met Bid · ANCOVA · p = <0.0001 · Mean difference (final values): -0.01 · 95% CI -0.13 to 0.12
  • Lina 5mg + Met qd vs Met Bid · ANCOVA · p = 0.8924 · Mean difference (final values): -0.01 · 95% CI -0.13 to 0.12
SecondaryComposite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 14 Weeks of Treatment, on no Occurrence of Moderate or Severe Gastrointestinal (GI) Side Effects During 14 Weeks of Treatment

The proportion of patients who achieved all the targets in a composite endpoint (HbA1c below 7.0% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe gastrointestinal (GI) side effects of metformin, as assessed by the investigators during 14 weeks of treatment)

Time frame:
14 weeks
Reported as:
Number · participants
Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 14 Weeks of Treatment, on no Occurrence of Moderate or Severe Gastrointestinal (GI) Side Effects During 14 Weeks of Treatment
participantsLina 5mg + Met qdMet Bid
Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 14 Weeks of Treatment, on no Occurrence of Moderate or Severe Gastrointestinal (GI) Side Effects During 14 Weeks of Treatment119148
Statistical analysis
  • Lina 5mg + Met qd vs Met Bid · Regression, Logistic · p = 0.8201 · Odds ratio (or): 0.960 · 95% CI 0.672 to 1.370Model includes treatment and continuous baseline HbA1c
SecondaryOccurence of Metformin Pre-specified Moderate to Severe GI Side Effects Assessed by Investigators During 14 Weeks of Treatment

Proportion of patients who experienced at least one metformin pre-specified moderate or severe GI side effect during 14 weeks

Time frame:
14 weeks
Reported as:
Number · participants
Occurence of Metformin Pre-specified Moderate to Severe GI Side Effects Assessed by Investigators During 14 Weeks of Treatment
participantsLina 5mg + Met qdMet Bid
Occurence of Metformin Pre-specified Moderate to Severe GI Side Effects Assessed by Investigators During 14 Weeks of Treatment2528
Statistical analysis
  • Lina 5mg + Met qd vs Met Bid · Regression, Logistic · p = 0.9397 · Odds ratio (or): 1.022 · 95% CI 0.582 to 1.796Model includes treatment and baseline HbA1c.
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) After 14 Weeks of Treatment

Means are adjusted by treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.

Time frame:
Baseline and 14 weeks
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) After 14 Weeks of Treatment
mg/dLLina 5mg + Met qdMet Bid
Change From Baseline in Fasting Plasma Glucose (FPG) After 14 Weeks of Treatment-24.5 ± 1.5-26.6 ± 1.4
Statistical analysis
  • Lina 5mg + Met qd vs Met Bid · ANCOVA · p = 0.3352 · Mean difference (final values): 2.0 · 95% CI -2.1 to 6.1
SecondaryMetformin Pre-specified GI Symptom Intensity Score Assessed by Investigators During 14 Weeks of Treatment

Patients could experience multiple events, therefore, multiple answers were possible for each patient.

Time frame:
14 weeks
Reported as:
Number · events
Metformin Pre-specified GI Symptom Intensity Score Assessed by Investigators During 14 Weeks of Treatment
eventsLina 5mg + Met qdMet Bid
Mild114153
Moderate3765
Severe61
Statistical analysis
  • Lina 5mg + Met qd vs Met Bid · Fisher Exact · p = 0.0308Fishers exact p-value presented due to small cell counts
SecondaryMetformin Pre-specified GI Symptom Intensity Score Assessed by Patients During 14 Weeks of Treatment

The intensity of the GI side effects was also assessed by the patients using VAS scaled from 0 to 10; higher scores indicate more severe events. Means are adjusted by treatment and continuous baseline HbA1c.

Time frame:
14 weeks
Reported as:
Mean · units on a scale
Metformin Pre-specified GI Symptom Intensity Score Assessed by Patients During 14 Weeks of Treatment
units on a scaleLina 5mg + Met qdMet Bid
Metformin Pre-specified GI Symptom Intensity Score Assessed by Patients During 14 Weeks of Treatment4.9 ± 0.24.4 ± 0.2
Statistical analysis
  • Lina 5mg + Met qd vs Met Bid · ANCOVA · p = 0.0545 · Mean difference (final values): 0.5 · 95% CI -0.0 to 1.0
SecondaryComposite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <6.5% After 14 Weeks of Treatment, and no Occurrence of Moderate or Severe Metformin Pre-specified GI Side Effects Assessed by Investigators

The proportion of patients who achieved all the targets in a composite endpoint (HbA1c below 6.5% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).

Time frame:
14 weeks
Reported as:
Number · participants
Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <6.5% After 14 Weeks of Treatment, and no Occurrence of Moderate or Severe Metformin Pre-specified GI Side Effects Assessed by Investigators
participantsLina 5mg + Met qdMet Bid
Composite Endpoint of Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <6.5% After 14 Weeks of Treatment, and no Occurrence of Moderate or Severe Metformin Pre-specified GI Side Effects Assessed by Investigators8395
Statistical analysis
  • Lina 5mg + Met qd vs Met Bid · Regression, Logistic · p = 0.9886 · Odds ratio (or): 0.997 · 95% CI 0.689 to 1.445
SecondaryOccurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment)

The proportion of patients who achieved a relative efficacy response (HbA1c lowering by at least 0.5% after 14 weeks of treatment).

Time frame:
14 weeks
Reported as:
Number · participants
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment)
participantsLina 5mg + Met qdMet Bid
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment)211257
Statistical analysis
  • Lina 5mg + Met qd vs Met Bid · Regression, Logistic · p = 0.2108 · Odds ratio (or): 0.797 · 95% CI 0.558 to 1.137
SecondaryOccurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment)

The proportion of patients who achieved a relative efficacy response (HbA1c lowering by at least 0.8% after 14 weeks of treatment).

Time frame:
14 weeks
Reported as:
Number · participants
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment)
participantsLina 5mg + Met qdMet Bid
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment)162187
Statistical analysis
  • Lina 5mg + Met qd vs Met Bid · Regression, Logistic · p = 0.9972 · Odds ratio (or): 0.999 · 95% CI 0.712 to 1.402
SecondaryComposite Endpoint of Occurence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment) and no Occurence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by the Investigators During 14 Weeks

The proportion of patients who achieved all the targets in a composite endpoint (HbA1c lowered by at least 0.5% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).

Time frame:
14 weeks
Reported as:
Number · participants
Composite Endpoint of Occurence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment) and no Occurence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by the Investigators During 14 Weeks
participantsLina 5mg + Met qdMet Bid
Composite Endpoint of Occurence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 14 Weeks of Treatment) and no Occurence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by the Investigators During 14 Weeks194236
Statistical analysis
  • Lina 5mg + Met qd vs Met Bid · Regression, Logistic · p = 0.2816 · Odds ratio (or): 0.832 · 95% CI 0.594 to 1.163
SecondaryChange From Baseline in Body Weight by Visit at Week 14

Means are adjusted by treatment, continuous baseline HbA1c and continuous baseline weight

Time frame:
Baseline and 14 weeks
Reported as:
Mean · kg
Change From Baseline in Body Weight by Visit at Week 14
kgLina 5mg + Met qdMet Bid
Change From Baseline in Body Weight by Visit at Week 14-0.44 ± 0.14-1.05 ± 0.13
Statistical analysis
  • Lina 5mg + Met qd vs Met Bid · ANCOVA · p = 0.0011 · Mean difference (final values): 0.62 · 95% CI 0.25 to 0.98
SecondaryComposite Endpoint of Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment) and no Occurrence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by Investigators During 14 Weeks

The proportion of patients who achieved all the targets in a composite endpoint (HbA1c lowered by at least 0.8% after 14 weeks of treatment; no occurrence of pre-specified moderate or severe GI side effects of metformin, as assessed by the investigators during 14 weeks of treatment).

Time frame:
14 weeks
Reported as:
Number · participants
Composite Endpoint of Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment) and no Occurrence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by Investigators During 14 Weeks
participantsLina 5mg + Met qdMet Bid
Composite Endpoint of Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.8% After 14 Weeks of Treatment) and no Occurrence of Moderate and Severe Metformin Pre-specified GI Side Effects Assessed by Investigators During 14 Weeks149175
Statistical analysis
  • Lina 5mg + Met qd vs Met Bid · Regression, Logistic · p = 0.7682 · Odds ratio (or): 0.951 · 95% CI 0.681 to 1.328
SecondaryChange From Baseline in HbA1c Over Time

Means are adjusted by treatment and continuous baseline HbA1c

Time frame:
Baseline, 2 weeks and 8 weeks
Reported as:
Mean · percent
Change From Baseline in HbA1c Over Time
percentLina 5mg + Met qdMet Bid
At week 2-0.28 ± 0.02-0.25 ± 0.02
At week 8-0.84 ± 0.04-0.78 ± 0.04

Adverse events

Collected over 14 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lina 5mg + Met qd—2/344 (0.6%)101/344 (29.4%)
Met Bid—7/345 (2%)121/345 (35.1%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventLina 5mg + Met qdMet Bid
CellulitisInfections and infestations0/3442/345
Pancreatitis acuteGastrointestinal disorders1/3440/345
AppendicitisInfections and infestations1/3440/345
Abdominal painGastrointestinal disorders0/3441/345
Epiploic appendagitisGastrointestinal disorders0/3441/345
Biliary dilatationHepatobiliary disorders0/3441/345
Cholecystitis acuteHepatobiliary disorders0/3441/345
Acute tonsillitisInfections and infestations0/3441/345
Comminuted fractureInjury, poisoning and procedural complications0/3441/345
Road traffic accidentInjury, poisoning and procedural complications0/3441/345
Most frequent other events
Most frequent other events
EventLina 5mg + Met qdMet Bid
DiarrhoeaGastrointestinal disorders62/34474/345
Urinary tract infectionInfections and infestations17/34434/345
Abdominal painGastrointestinal disorders23/34429/345
NauseaGastrointestinal disorders23/34424/345

Baseline characteristics

Treated set (TS): all patients treated with at least 1 dose of randomised study medication

Age, Continuous
Age, Continuous(years)Lina 5mg + Met qdMet BidTotal
Mean53.1 ± 10.752.9 ± 10.753.0 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Lina 5mg + Met qdMet BidTotal
Female175187362
Male169158327
08

Study locations

90 sites
  • 1218.60.90001 Boehringer Ingelheim Investigational Site
    Dhaka, Bangladesh
  • 1218.60.90002 Boehringer Ingelheim Investigational Site
    Dhaka, Bangladesh
  • 1218.60.90003 Boehringer Ingelheim Investigational Site
    Dhaka, Bangladesh
  • 1218.60.32001 Boehringer Ingelheim Investigational Site
    Genk, Belgium
  • 1218.60.32005 Boehringer Ingelheim Investigational Site
    Ham, Belgium
  • 1218.60.32002 Boehringer Ingelheim Investigational Site
    Hasselt, Belgium
  • 1218.60.32004 Boehringer Ingelheim Investigational Site
    Natoye, Belgium
  • 1218.60.32003 Boehringer Ingelheim Investigational Site
    Tremelo, Belgium
  • 1218.60.20009 Boehringer Ingelheim Investigational Site
    Calgary, Alberta, Canada
  • 1218.60.20003 Boehringer Ingelheim Investigational Site
    Burnaby, British Columbia, Canada
  • 1218.60.20014 Boehringer Ingelheim Investigational Site
    Coquitlam, British Columbia, Canada
  • 1218.60.20010 Boehringer Ingelheim Investigational Site
    Surrey, British Columbia, Canada
  • 1218.60.20004 Boehringer Ingelheim Investigational Site
    Halifax, Nova Scotia, Canada
  • 1218.60.20012 Boehringer Ingelheim Investigational Site
    Corunna, Ontario, Canada
  • 1218.60.20015 Boehringer Ingelheim Investigational Site
    Hamilton, Ontario, Canada
  • 1218.60.20006 Boehringer Ingelheim Investigational Site
    London, Ontario, Canada
  • 1218.60.20013 Boehringer Ingelheim Investigational Site
    London, Ontario, Canada
  • 1218.60.20002 Boehringer Ingelheim Investigational Site
    Sarnia, Ontario, Canada
  • 1218.60.20011 Boehringer Ingelheim Investigational Site
    Sarnia, Ontario, Canada
  • 1218.60.20005 Boehringer Ingelheim Investigational Site
    Strathroy, Ontario, Canada
  • 1218.60.20007 Boehringer Ingelheim Investigational Site
    Toronto, Ontario, Canada
  • 1218.60.20016 Boehringer Ingelheim Investigational Site
    Toronto, Ontario, Canada
  • 1218.60.20001 Boehringer Ingelheim Investigational Site
    St-Romuald, Quebec, Canada
  • 1218.60.86001 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 1218.60.86003 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 1218.60.86011 Boehringer Ingelheim Investigational Site
    Changsha, China
  • 1218.60.86012 Boehringer Ingelheim Investigational Site
    Chengdu, China
  • 1218.60.86010 Boehringer Ingelheim Investigational Site
    Chongqing, China
  • 1218.60.86013 Boehringer Ingelheim Investigational Site
    Hubei, China
  • 1218.60.86014 Boehringer Ingelheim Investigational Site
    Hubei, China
  • 1218.60.86006 Boehringer Ingelheim Investigational Site
    Nanjing, China
  • 1218.60.86007 Boehringer Ingelheim Investigational Site
    Nanjing, China
  • 1218.60.86005 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1218.60.86009 Boehringer Ingelheim Investigational Site
    Shenyang, China
  • 1218.60.86008 Boehringer Ingelheim Investigational Site
    Wuxi, China
  • 1218.60.49007 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1218.60.49008 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1218.60.49005 Boehringer Ingelheim Investigational Site
    Dresden, Germany
  • 1218.60.49004 Boehringer Ingelheim Investigational Site
    Erfurt, Germany
  • 1218.60.49006 Boehringer Ingelheim Investigational Site
    Frankfurt, Germany
  • 1218.60.49003 Boehringer Ingelheim Investigational Site
    Hamburg, Germany
  • 1218.60.49002 Boehringer Ingelheim Investigational Site
    Neuwied, Germany
  • 1218.60.49001 Boehringer Ingelheim Investigational Site
    Unterschneidheim, Germany
  • 1218.60.50001 Boehringer Ingelheim Investigational Site
    Guatemala, Guatemala
  • 1218.60.50002 Boehringer Ingelheim Investigational Site
    Guatemala, Guatemala
  • 1218.60.50003 Boehringer Ingelheim Investigational Site
    Guatemala, Guatemala
  • 1218.60.85001 Boehringer Ingelheim Investigational Site
    Hong Kong, Hong Kong
  • 1218.60.85002 Boehringer Ingelheim Investigational Site
    Hong Kong, Hong Kong
  • 1218.60.91004 Boehringer Ingelheim Investigational Site
    Aurangabad, India
  • 1218.60.91010 Boehringer Ingelheim Investigational Site
    Bangalore, India
  • 1218.60.91005 Boehringer Ingelheim Investigational Site
    Coimbatore, India
  • 1218.60.91008 Boehringer Ingelheim Investigational Site
    Kolkata, India
  • 1218.60.91001 Boehringer Ingelheim Investigational Site
    Nagpur, India
  • 1218.60.91007 Boehringer Ingelheim Investigational Site
    Nagpur, India
  • 1218.60.91003 Boehringer Ingelheim Investigational Site
    Pune, India
  • 1218.60.91006 Boehringer Ingelheim Investigational Site
    Pune, India
  • 1218.60.96001 Boehringer Ingelheim Investigational Site
    Beirut, Lebanon
  • 1218.60.96002 Boehringer Ingelheim Investigational Site
    Beirut, Lebanon
  • 1218.60.96004 Boehringer Ingelheim Investigational Site
    Byblos, Lebanon
  • 1218.60.96003 Boehringer Ingelheim Investigational Site
    Hazmieh, Lebanon
  • 1218.60.96005 Boehringer Ingelheim Investigational Site
    Saida, Lebanon
  • 1218.60.52005 Boehringer Ingelheim Investigational Site
    Aguascalientes, Mexico
  • 1218.60.52003 Boehringer Ingelheim Investigational Site
    Cuernavaca, Mexico
  • 1218.60.52001 Boehringer Ingelheim Investigational Site
    Durango, Mexico
  • 1218.60.52002 Boehringer Ingelheim Investigational Site
    Durango, Mexico
  • 1218.60.52004 Boehringer Ingelheim Investigational Site
    Monterrey, Mexico
  • 1218.60.51001 Boehringer Ingelheim Investigational Site
    Lima, Peru
  • 1218.60.51002 Boehringer Ingelheim Investigational Site
    Lima, Peru
  • 1218.60.51004 Boehringer Ingelheim Investigational Site
    Piura, Peru
  • 1218.60.63001 Boehringer Ingelheim Investigational Site
    Cebu City, Philippines, Philippines
  • 1218.60.63004 Boehringer Ingelheim Investigational Site
    Iloilo City, Philippines, Philippines
  • 1218.60.63003 Boehringer Ingelheim Investigational Site
    Manila, Philippines
  • 1218.60.63002 Boehringer Ingelheim Investigational Site
    Marikina City, Philippines, Philippines
  • 1218.60.63005 Boehringer Ingelheim Investigational Site
    Quezon City, Philippines
  • 1218.60.34001 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 1218.60.34002 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 1218.60.34003 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 1218.60.34004 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 1218.60.34006 Boehringer Ingelheim Investigational Site
    Borges del Camp- Tarragona, Spain
  • 1218.60.34005 Boehringer Ingelheim Investigational Site
    Centelles, Spain
  • 1218.60.34009 Boehringer Ingelheim Investigational Site
    Granada, Spain
  • 1218.60.34008 Boehringer Ingelheim Investigational Site
    L'Hospitalet de Llobregat, Spain
  • 1218.60.34007 Boehringer Ingelheim Investigational Site
    Mataró, Spain
  • 1218.60.34010 Boehringer Ingelheim Investigational Site
    Valencia, Spain
  • 1218.60.88006 Boehringer Ingelheim Investigational Site
    Chiayi County, Taiwan
  • 1218.60.88003 Boehringer Ingelheim Investigational Site
    Kaohsiung,, Taiwan
  • 1218.60.88001 Boehringer Ingelheim Investigational Site
    Taichung, Taiwan
  • 1218.60.88007 Boehringer Ingelheim Investigational Site
    Taichung, Taiwan
  • 1218.60.88002 Boehringer Ingelheim Investigational Site
    Tainan,, Taiwan
  • 1218.60.88004 Boehringer Ingelheim Investigational Site
    Taipei County, Taiwan
09

References and documents

Publications

  • Ji L, Zinman B, Patel S, Ji J, Bailes Z, Thiemann S, Seck T. Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naive patients with type 2 diabetes: a double-blind randomized trial. Adv Ther. 2015 Mar;32(3):201-15. doi: 10.1007/s12325-015-0195-3. Epub 2015 Mar 25. PubMed 25805187 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2011
First posted
Sep 22, 2011
Start
Nov 2011
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Jun 3, 2014
Last update
Nov 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01438814
Responsible party
Sponsor
First posted
Sep 22, 2011
Start date
Nov 2011
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Jun 3, 2014
Last update
Nov 25, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion